Patient access to orphan drugs

Expert Opinion on Orphan Drugs

Volumn 5, Issue 12, 2017, Pages 923-932

  Cohen, Joshua P ^a   Awatin, Josephine G ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

budget impact; cost effectiveness; formulary management tools; Orphan Drug Act; Orphan drugs; patient access; reimbursement

Indexed keywords

ORPHAN DRUG;

ARTICLE; DRUG APPROVAL; DRUG COST; HUMAN; PRIORITY JOURNAL; REIMBURSEMENT; UNITED STATES;

EID: 85036668122     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1080/21678707.2017.1402676     Document Type: Article

References (14)

1. Food and Drug Administration (FDA). Orphan drug designations and approvals. Available from: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/
2. Bach P, Saltz L, Wittes R, In cancer care, cost matters. New York Times. Oct 14, 2012.
3. Gammie T, Lu C, Ud-Din Babar Z., Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries. PLoS. 2015 Oct 9;10: e0140002. DOI:10.1371/journal.pone.0140002.
4. Hyde R, Dobrovolny D., Orphan drug pricing and payer management in the United States: are we approaching the tipping point? Am Health Drug Benefits. 2010;3(1):15–23.
5. Cohen JP. Patient access to orphan drugs faces new sets of challenges. Formulary J. 2014. Available from: http://formularyjournal.modernmedicine.com/formulary-journal/news/patient-access-orphan-drugs-faces-new-set-challenges?page=full
6. Faden L, Huskamp H. Institute of medicine committee on accelerating rare diseases research and orphan product development. In: Field MJ, Boat TF, Editors. Rare diseases and orphan products: accelerating research and development. Washington (DC): National Academies Press; 2010.
7. NORD (National Organization for Rare Disorders). 2006. Letter to Mark B. McClellan, M.D., Ph.D., Administrator of CMS: orphan drug coverage in Medicare part D formularies 2006 Jan. Available from: http://www.rarediseases.org/news/pdf/Final_ltr_CMS_011006_V2.pdf
8. Divino V, DeKoven M, Kleinrock M, et al. Orphan drug expenditures in the United States: a historical and prospective analysis, 2007–18. Health Aff. 2016;35(9):1588–1594.
9. XcendaPayerPulse® survey. 2014. Available from: http://www.xcenda.com/Insights-Library/Payer-Perspectives/Payer-Trends-Impacting-the-Orphan-Drug-Market/
10. Handfield R, Feldstein J. Insurance companies’ perspectives on the orphan drug pipeline. American Health Drug Benefits. 2013;6(9):589–598.
11. McCain J. Could QALYs help in assessing high-priced cancer treatments? Manag Care. 2013;22(12):32–37.
12. Simoens S, Picavet E, Dooms M, et al. Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum. Appl Health Econ Health Policy. 2013;11(1):1–3.
13. Rodriguez-Monguio R, Spargo T, Seoane-Vazquez E. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs? Orphanet J Rare Dis. 2017;12:1–10.
14. General Accounting Office Report. 2016. Physician-administered drugs: comparison of payer payment methodologies. Available from: http://www.gao.gov/assets/680/678784.pdf